Jan 15 (Reuters) – Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion to expand its vascular pipeline.
The deal values Penumbra at $374 per share, a premium of about 19.3% to its last close. Penumbra’s shares rose over 10% in premarket trading, while Boston’s shares fell 4%.
The transaction is expected to be completed in 2026.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
